Research Type: Academic Literature
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection
Read More
-
Abandon Biosimilars as Biologics are Natural Monopolies
Read More
-
List Price, Net Price, and the Rebate Caught in the Middle
Read More
-
Expansion of the Medicare 340B Payment Program
Read More
-
The “Netflix Model” of Financing Hepatitis C Treatment
Read More
-
Cardiovascular Drugs Not Price Aligned with Value in US
Read More
-
Perspective on National Coverage Analysis of CAR-T Therapies
Read More
-
Spending On Prescription Drugs In The US: Where Does All The Money Go?
Read More
-
Money-Back Guarantees for Expensive Drugs: Wolf’s Clothing but a Sheep Underneath
Read More
-
Association of Rebates in Part D with Patient OOP and Federal Spending
Read More